BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-1166@pharmaconomics
DTSTAMP:20260707T003824Z
DTSTART;VALUE=DATE:20260930
DTEND;VALUE=DATE:20261001
SUMMARY:ARGX Phase 2 — ARGX-121 (estimated date)
DESCRIPTION:Phase 2 trial results for ARGX-121 in IgA nephropathy (IgAN) are due ~ Sep 30\, 2026. A clean hit validates the program\; a miss can gap the stock down hard.\n\nPrimary source: https://www.sec.gov/Archives/edgar/data/1697862/000169786226000010/a09earningspressreleaseq4.htm\n\nTrack it: https://pharmaconomics.com/e/1166
URL:https://pharmaconomics.com/e/1166
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:ARGX catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR